1. Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation
- Author
-
Keiichi Fukuda, Takehiro Kimura, Seiji Takatsuki, Shin Kashimura, Yoko Tanimoto, Nobuhiro Nishiyama, Yoshinori Katsumata, Yukinori Ikegami, Kojiro Tanimoto, Yoshiyasu Aizawa, Kohei Inagawa, Kotaro Fukumoto, and Takahiko Nishiyama
- Subjects
Rivaroxaban ,medicine.medical_specialty ,Cerebral infarction ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,Warfarin ,Atrial fibrillation ,Catheter ablation ,030204 cardiovascular system & hematology ,medicine.disease ,Asymptomatic ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Cardiology ,medicine.symptom ,Cardioversions ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Objectives This randomized study compared uninterrupted rivaroxaban therapy with warfarin therapy as prophylaxis against catheter ablation (CA)-induced asymptomatic cerebral infarction (ACI) and identified the risk factors of rivaroxaban. Background The reported incidence of ACI during CA for atrial fibrillation (AF) remains at 10% to 30%, and periprocedural oral anticoagulation could affect this incidence. Methods Patients with nonvalvular AF undergoing radiofrequency CA were randomly assigned to receive either uninterrupted rivaroxaban or warfarin as periprocedural anticoagulation therapy. CA was performed after at least 1 month of adequate anticoagulation. Cerebral magnetic resonance imaging (MRI) was performed within 2 weeks before and 1 day after CA to detect ACI. Results A total 132 patients were enrolled; 127 (median: 60.0 years of age; 83.5% males; 64.6% incidence of paroxysmal AF) complied with the study protocol and were analyzed; 64 patients received rivaroxaban, and 63 patients received warfarin. The rates of CA-induced ACI in the rivaroxaban group (15.6% [10 of 64 patients]) were similar to those in the warfarin group (15.9% [10 of 63 patients]; p = 1.000). No thromboembolic events developed; no differences in major or nonmajor bleeding rates were observed between the 2 drug groups (3.1% vs. 1.6%, respectively, or 18.8% vs. 19.0%, respectively). Multiple regression analysis indicated that the presence of deep and subcortical white matter hyperintensity (p = 0.002; odds ratio [OR]: 5.323) and the frequency of cardioversions (p = 0.016; OR: 1.250) were associated with the incidence of ACI. Conclusions No notable differences were found between the incidence of CA-induced ACI in the rivaroxaban group and that in the warfarin group in this randomized study.
- Published
- 2018
- Full Text
- View/download PDF